Exor N.V. (EYX)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 67.15 |
|---|---|
| 52-week range | 59.85 – 77.90 |
| Return, 1 month / 3 months | −8.0% / −1.0% |
| Return, 1 year / 3 years | −11.3% / −17.1% |
| Trend | Below its 200-day average |
| RSI (14) | 36 |
| Volatility (1 year) | 26.0% |
| Worst drawdown (1 year) | -18.7% |
| Average daily value traded | 0.07M EUR |
| Dividend yield | 0.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Exor is an investment holding company controlled by the Agnelli family and based in the Netherlands. It owns and manages stakes in a range of businesses, including carmakers and industrial vehicle makers, through its portfolio of controlled companies and minority investments. Its holdings span automotive, industrial equipment, media and other sectors, and it takes long-term positions in companies across Europe and North America. Exor also makes investments in newer businesses in technology and healthcare.
Exor N.V. trades under the code EYX on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Exor N.V. (EYX) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 67.15 on 23 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 330 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 11.3% and over the last three months it fell 1.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 59 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -2.5% | ||
| From 52-week high | -12.9% | ||
| Momentum | 49 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -1.0% | ||
| 6-month return | -2.1% | ||
| 12-month return, skipping the last month | -3.6% | ||
| Stability (higher is calmer) | 81 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -18.7% | ||
| Liquidity | 40 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.07M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 15 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.7% | ||
| Years with dividends | 4 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | −2.6% |
|---|---|
| 1 month | −8.0% |
| 3 months | −1.0% |
| 6 months | −2.1% |
| 1 year | −11.3% |
| 3 years | −17.1% |
| 5 years | +214.1% |
Signals
| 50-day / 200-day average | 70.53 / 68.88 |
|---|---|
| Golden / death cross (60 days) | Golden, 38 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.14 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 25 May 2026 | EUR 0.4900 |
| 26 May 2025 | EUR 0.4900 |
| 30 May 2024 | EUR 0.4600 |
| 2 Jun 2023 | EUR 0.4400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.